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Abstract
Objective: Obesity is considered to be the strongest predictive factor for cardio-metabolic 
risk in women with polycystic ovary syndrome (PCOS). The aim of the study was to 
compare blood pressure (BP) in normal weight women with PCOS and controls matched 
for age and BMI.
Methods: From a Nordic cross-sectional base of 2615 individuals of Nordic ethnicity, we 
studied a sub cohort of 793 normal weight women with BMI < 25 kg/m2 (512 women 
with PCOS according to Rotterdam criteria and 281 age and BMI-matched controls). 
Participants underwent measurement of BP and body composition (BMI, waist-hip ratio), 
lipid status, and fasting BG. Data were presented as median (quartiles).
Results: The median age for women with PCOS were 28 (25, 32) years and median BMI 
was 22.2 (20.7, 23.4) kg/m2. Systolic BP was 118 (109, 128) mmHg in women with PCOS 
compared to 110 (105, 120) mmHg in controls and diastolic BP was 74 (67, 81) vs 70 
(64, 75) mmHg, both P < 0.001. The prevalence of women with BP ≥ 140/90 mmHg was 
11.1% (57/512) in women with PCOS vs 1.8% (5/281) in controls, P < 0.001. In women  
≥ 35 years the prevalence of BP ≥ 140/90 mmHg was comparable in women with PCOS 
and controls (12.7% vs 9.8%, P = 0.6). Using multiple regression analyses, the strongest 
association with BP was found for age, waist circumference, and total cholesterol in 
women with PCOS.
Conclusions: Normal weight women with PCOS have higher BP than controls. BP and 
metabolic screening are relevant also in young normal weight women with PCOS.
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Polycystic ovary syndrome (PCOS) is the most common 
endocrine disorder in women of reproductive age, with 
a prevalence of 10–20% when the Rotterdam criteria are 
used (1). The PCOS diagnosis is based on at least two out of 
three criteria: clinical or biochemical hyperandrogenism 
(HA), chronic oligo-anovulation and polycystic ovaries, 
with exclusion of other etiologies (2).
Women with PCOS are characterized by abdominal 
obesity, insulin resistance, dyslipidemia, and increased 
risk of the metabolic syndrome, which could be associated 
with increased risk of cardiovascular disease (CVD) (3). The 
definition of the metabolic syndrome includes elevated 
blood pressure (BP) (3). It is estimated that more than 30% 
of women with PCOS have BP > 130/85 mmHg (4) and 
also young women with PCOS have around three times 
increased risk of hypertension (HT) compared to controls 
(3, 5, 6, 7). In accordance, the recent international PCOS 
guideline recommends that BP should be measured by 
time of PCOS diagnosis, and thereafter annually in all 
women with PCOS (8).
The cardio-metabolic risk in PCOS could differ by 
PCOS phenotype, and especially the long-term cardio-
metabolic risk in normal weight women with PCOS is 
unknown. In a Danish national register-based study 
including 19,199 women with PCOS (9), we recently 
reported that the prospective risk of developing type 
2 diabetes was not increased in normal weight Danish 
women with PCOS compared to controls (10). This has 
been confirmed in other studies by our group (11, 12). 
However, the risk of CVD including HT was significantly 
increased in women with PCOS compared to controls also 
after adjusting for baseline BMI (5). Furthermore, 24% of 
women with PCOS in a local subset of the study cohort, 
who developed CVD, were lean by the time of PCOS 
diagnosis (5). These findings suggested that the risk of 
CVD including HT was attenuated but not normalized in 
normal weight women with PCOS. In contrast, two recent 
meta-analyses did not find increased risk of the metabolic 
syndrome including HT in normal weight women with 
PCOS (7, 13). Whether BP is higher in normal weight 
women with PCOS compared to controls therefore awaits 
clarification.
Determinants of BP in women with PCOS have not 
been extensively studied. Obesity is considered most 
important for cardio-metabolic risk in women with PCOS 
(7, 14), but the importance of BMI and/or central obesity 
for vascular health in normal weight women with PCOS is 
undetermined. Testosterone levels could be an important 
modifier of vascular health in PCOS, but whether 
testosterone has a protective or unfavorable impact on the 
risk of CVD in PCOS is debated (7, 15). We are not aware 
of studies investigating associations between testosterone 
levels and BP in normal weight study populations of 
women with PCOS. Furthermore, the international 
guidelines for PCOS recommend measurements of lipids 
and blood glucose in all women with PCOS (8). The 
importance of measuring these metabolic risk markers for 
vascular health in normal weight women with PCOS is 
debated (10, 11, 16).
The aims of this study were (i) to investigate if normal 
weight women with PCOS have higher BP than controls 
and (ii) to investigate possible determinants for BP in 
normal weight women with PCOS.
Materials and methods
Inclusion criteria
Women diagnosed with PCOS from Denmark, Finland, 
Norway and Sweden and with available BP assessment 
were included in this study. All women fulfilled the 
Rotterdam criteria for PCOS (2) and were of Nordic 
origin. Data regarding lipid status, testosterone levels, 
and glucose tolerance in the whole study cohort have 
been published earlier (11, 16, 17). Here we present data 
from women ≥ 20 years of age and BMI ≤ 25 kg/m2. 
Participants and controls were recruited from outpatient 
clinics, hospitals, advertisements in newspapers, hospital 
staff, and medical students as previously described (11, 16, 
17). The controls were recruited from outpatient clinics, 
hospital staff, medical students, or by advertisement.
Exclusion criteria
Women with use of hormonal contraceptives in the 
past 2 months prior to enrollment, ongoing pregnancy, 
breastfeeding, or serious endocrine disease were not 
included in the study. Controls had no signs or symptoms 
of PCOS.
The study was approved by the Ethics committee 
region of Southern Denmark, Ethics committee of the 
Northern Ostrobothnia Hospital District, Regional 
committee for medical and health research ethics – Mid-
Norway, Regional committee for medical and health 
research ethics – South-East Norway, Ethical review 
committee in Uppsala, Etikprövnings-myndigheten, 
Stockholm and Regionala etikprövningsnämnden in 
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Gothenburg (11, 16, 17). Consent has been obtained 
from each patient or subject after full explanation of the 
purpose and nature of all procedures used.
Study protocol
All women with PCOS and controls underwent clinical 
examination: measurement of height, weight, waist 
and hip circumference, Ferriman-Gallwey (FG)-score 
for hirsutism, and transvaginal ultrasound. Clinical 
hyperandrogenism (hirsutism) was diagnosed when a 
woman had FG-score ≥ 8.
BP was measured while supporting the upper limb, 
ensuring the cuff was at heart level, using a correct size 
of the cuff, and not talking with the person during the 
process. The women avoided caffeine, smoking, and 
exercise for at least 30 min before the measurement.
Protocols regarding measurement of BP varied 
between the seven different sites in the following manner:
 • Odense University Hospital: Patients had 10 min rest 
while sitting, before one measurement was recorded.
 • Oulu University Hospital: Patients had 15 min rest 
while sitting. BP was measured twice with 1 min 
interval. The mean of the two measurements was 
recorded.
 • Oslo University Hospital: Patients had 15 min rest 
while sitting. BP was measured twice with 2 min 
interval and the lowest BP was recorded.
 • Norwegian University of Science and Technology: 
Patients had 10 min rest while sitting. BP was measured 
three times at least 2 min apart. The mean of the 
second and third BP measurement was used.
 • Karolinska Institutet, Department of Women’s and 
Children’s Health: Patients had 5 min rest while sitting, 
before one measurement was recorded.
 • University of Gothenburg, Sahlgrenska University 
Hospital: Patients had 5 min rest in a supine position. 
BP was measured two times with 5 min interval, and 
the mean was recorded.
 • Uppsala University: Patients had 30 min rest while 
sitting. BP was measured three times with 5 min 
intervals and the mean was recorded.
Assays
Metabolic variables (glucose, lipid profile) were assayed by 
means of the routine methods used in the laboratories of 
the different study centers (11). Plasma total cholesterol, 
high-density lipoprotein (HDL), cholesterol, and 
triglyceride (TG) were analyzed by enzymatic colorimetric 
reactions (Modular P, Roche), and low-density lipoprotein 
(LDL) cholesterol was calculated using the Friedewald 
equation (18). According to the Nordic Reference Interval 
Project 2000, the reference ranges for the serum lipid levels 
were similar in all subpopulations of the study. Serum 
testosterone was measured by liquid chromatography–
mass spectrometry (LC/MS), and SHBG was measured by 
chemiluminometric immunoassays as reported earlier 
(11, 17). In Danish women, serum testosterone was 
analyzed using a specific radio-immunoassay after ether 
extraction (19). This method shows a close correlation 
with the determination of testosterone levels using mass 
spectrometry (19).
Free androgen index (FAI) was calculated by dividing 
total testosterone with SHBG and multiplying by 100.
Statistics
The primary study outcome was BP. We aimed to compare 
differences in BP between normal weight women with 
PCOS vs controls and determinants of BP in women with 
PCOS. Given the inconsistency of previous study findings 
in lean women with PCOS, we did not perform a power 
calculation. We wanted to study two comparable groups 
with respect to age and BMI distribution in the patient 
and control groups. Hence, 512 women with PCOS were 
matched individually with one woman in the control 
group (n = 281) according to age (age range 20–57 years), 
and BMI (range 18.8–24.8 kg/m2 in the PCOS group and 
18.7–24.7 kg/m2 in the control group, 2.5–97.5 percentile 
interval). Matching was performed according to the 
nearest year of birth and BMI unit.
Epidemiological studies have evaluated the 
association of SBP, DBP, pulse pressure, mean BP, and 
mid/BP with CVD outcomes. Among these, SBP and 
DBP are consistently best associated with CVD risk and 
are prioritized in this study (20, 21). BP 140/90 was used 
as threshold BP according to the European guidelines 
(22). Data are presented as median (quartiles) and n (%). 
Differences between women with PCOS and controls were 
evaluated by Mann–Whitney test (continuous variables) 
and Chi-square test. Country of inclusion was taken into 
account by entering country code as an independent 
variable (1: Denmark, 2: Finland, 3: Norway, 4: Sweden). In 
these analyses, we entered clinical relevant study outcome 
(BP, age, etc.) as the dependent variable and country code 
and patient/controls as independent variables.
Several of the biochemical markers exhibited some 
deviation from a Gaussian distribution and we examined 
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bivariate association between DBP, SBP, clinical, and 
biochemical characteristics in women with PCOS and 
in controls separately by non-parametric Spearman 
correlation (r-values and P-levels).
Multiple linear regression analysis was used to examine 
the effect of lipid status, glucose status, and testosterone on 
SBP and DBP, respectively, in women with PCOS. Variables 
included in the regression analyses were selected based on 
closest association with SBP and DBP, respectively, based 
on results from bivariate correlation analyzes. The clinical 
setting differed at the study centers, and country code was 
entered as an independent variable in regression analyses. 
All models were corrected for age, waist circumference, 
and country of study inclusion (1: Denmark, 2: Finland, 3: 
Norway, 4: Sweden). Data were presented as β-coefficients 
(95% CI) and adjusted R2 values. In all regression models, 
model assumptions were validated through comprehensive 
residual analyses, as well as inspection of linearity and 
homogeneity of variance, and multicollinearity was 
assessed through variance inflation factors.
IBM SPSS statistics 25 statistical package was used. A 
P-value < 0.05 was considered significant.
Results
Clinical and biochemical characteristics of women 
with PCOS and age- and weight-matched controls are 
presented in Table 1. The number of patients included 
from Denmark was n = 175 (one study center), Sweden 
n = 102 (three study centers), Norway n = 85 (two study 
centers), and Finland n = 149 (one study center).
SBP and DBP were significantly higher in women with 
PCOS compared to controls.
Total testosterone, FAI, and HbA1c were higher, and 
SHBG levels were lower in women with PCOS vs controls, 
whereas waist circumference, WHR, lipid status, and 
fasting BG were comparable in the two study cohorts. All 
results, except HbA1c, remained significant after adjusting 
for country of study inclusion (Table 1).
The prevalence of BP ≥ 140/90 mmHg in different 
age groups in women with PCOS and controls is shown 
in Table 2. BP ≥ 140/90 mmHg was observed in 11.1% 
(57/512) women with PCOS compared to 1.8% (5/281) 
controls. Furthermore, both SBP ≥ 140 mmHg (8.2% PCOS 
vs 1.7% controls) and DBP ≥ 90 mmHg (7.4% PCOS vs 0.3% 
controls) were higher than in controls. In women < 35 
years, the prevalence of BP ≥ 140/90 mmHg was 10.9% 
(47/433) in women with PCOS compared to 0% (0/230) 
in controls, P <0.001. In women ≥ 35 years the prevalence 
of BP ≥ 140/90 mmHg was 12.7% (10/79) in women with 
PCOS compared to 9.8% (5/51) in controls, P = 0.62.
Characteristics in women with PCOS according to 
BP < or ≥ 140/90 mmHg are shown in Table 3. Women 
with BP ≥ 140/90 mmHg had higher waist circumference, 
Table 1 Characteristics of normal-weight women with PCOS and age and BMI matched controls.
PCOS Controls
P-value P-value*n n
SBP (mmHg) 512 118 (109, 128) 110 (105, 120) 281 <0.001 0.01
DBP (mmHg) 512 74 (67, 81) 70 (64, 75) 281 <0.001 <0.001
Age (years) 512 28 (25, 32) 27 (24, 31) 281 0.62 0.34
BMI (kg/m2) 512 22.2 (20.7, 23.4) 22.0 (20.5, 23.3) 281 0.31 0.25
Waist 472 77 (72, 81) 76 (73, 81) 123 0.27 0.50
WHR 466 0.77 (0.74, 0.83) 0.77 (0.75, 0.82) 123 0.53 0.83
FG score 293 4 (2, 8) 0 118 <0.001 <0.001
T-testosterone (nmol/L) 360 1.5 (1.1, 2.0) 0.8 (0.6, 1.0) 248 <0.001 <0.001
SHBG (nmol/L) 484 54 (41, 71) 71 (56, 93) 246 <0.001 <0.001
Androgen index 339 0.26 (0.17, 0.43) 0.11 (0.08, 0.15) 246 <0.001 <0.001
Cholesterol (mmol/L) 326 4.4 (3.9, 5.0) 4.5 (3.9, 5.0) 111 0.70 0.51
TG (mmol/L) 323 0.8 (0.6, 1.0) 0.8 (0.6, 0.9) 111 0.79 0.85
LDL (mmol/L) 298 2.4 (2.0, 2.9) 2.4 (1.9, 2.9) 111 0.10 0.97
HDL (mmol/L) 306 1.6 (1.4, 1.8) 1.6 (1.4, 1.9) 111 0.67 0.81
BG fasting (mmol/L) 395 4.8 (4.6, 5.1) 4.9 (4.5, 5.2) 93 0.78 0.23
HbA1c (%) 205 5.2 (4.9, 5.3) 4.8 (4.7, 5.0) 43 <0.001 0.36
Smoking (yes), n (%) 447 64 (14.3%) 10 (9.4%) 106 0.11 0.54
Anovulation (yes), n (%) 506 430 (84.9%)
PCOS (yes), n (%) 477 406 (85.1%)
HA (yes), n (%) 475 269 (56.6%)
PCOS + anov (yes), n (%) 426 219 (51.4%)
Data presented as median (interquartile range) or n (%). P-values between women with PCOS and controls.
*P-value adjusted for country of study-inclusion (1: Denmark, 2: Finland, 3: Norway, 4: Sweden).
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WHR, FAI, total cholesterol, fasting BG, and lower rate of 
anovulation and polycystic ovaries compared to women 
with BP < 140/90 mmHg.
Bivariate associations with BP are shown in Table 4. 
In women with PCOS, SBP, and DBP were positively 
correlated with BMI, waist circumference, WHR, total 
testosterone, lipid status (total cholesterol, TG, LDL), and 
fasting BG. The highest R-values were found for WHR, 
lipid status, and fasting BG. In controls, the highest 
R-values were found in associations between BP and age, 
BMI, waist circumference, and WHR.
Multiple regression analyses in women with PCOS are 
shown in Tables 5 and 6.
SBP
Age and waist were significant predictors of SBP in the 
crude model. In adjusted analyses, the best individual 
marker of SBP was age and cholesterol. The R2 value of the 
fully adjusted model was 0.39.
DBP
Waist circumference and age was significantly associated 
with DBP in the crude model. In adjusted analyses, the 
best individual marker of DBP was cholesterol. The R2 
value of the fully adjusted model was 0.39.
Table 2 Number and percentage of women with PCOS and controls with blood pressure ≥ 140/90 according to age (n = 512 
PCOS, 281 controls).
Age (years)
SBP ≥ 140 mmHg DBP ≥ 90 mmHg BP ≥ 140/90 mmHg
PCOS Control PCOS Control PCOS Control
<25 8/110 0/81 7/110 0/81 12/110 0/81
25–29 14/199 0/109 11/199 0/109 18/199 0/109
30–34 12/124 0/40 13/124 0/40 17/124 0/40
35–39 5/59 2/29 5/59 0/29 7/59 2/29
≥40 3/20 3/22 2/20 1/22 3/20 3/22
Total 42/512 (8.2%) 5/281 (1.7%) 38/512 (7.4%) 1/281 (0.3%) 57/512 (11.1%) 5/281 (1.8%)
Chi test <0.003 <0.01 <0.001
Chi test performed within each BP group (SBP, DBP, and BP) PCOS vs controls.
Table 3 Characteristics in women with PCOS divided according to BP (n = 512).
BP ≥ 140/90 BP < 140/90
P-valuen n
SBP (mmHg) 57 142 (138, 150) 116 (108, 124) 455 <0.001
DBP (mmHg) 67 92 (86, 96) 72 (67, 80) 455 <0.001
Age (years) 57 29 (26, 34) 28 (25, 32) 455 0.16
BMI (kg/m2) 57 22.5 (20.9, 24.0) 22.1 (20.7, 23.3) 455 0.14
Waist (cm) 53 80 (73, 85) 76 (71, 81) 419 0.02
WHR 52 0.80 (0.76, 0.85) 0.77 (0.73, 0.83) 414 0.02
FG score 21 3 (1, 7) 4 (2, 8) 272 0.40
T-testosterone (nmol/L) 46 1.60 (1.25, 2.27) 1.50 (1.10, 2.00) 359 0.14
SHBG (nmol/L) 62 54 (41, 77) 53 (39, 70) 485 0.63
FAI 32 0.36 (0.19, 0.47) 0.26 (0.17, 0.42) 307 0.04
Cholesterol (mmol/L) 40 4.8 (4.1, 5.4) 4.4 (3.9, 4.9) 286 0.01
TG (mmol/L) 39 0.8 (0.6, 0.9) 0.7 (0.6, 1.0) 259 0.54
LDL (mmol/L) 39 2.6 (2.1, 3.3) 2.4 (1.9, 2.9) 267 0.06
HDL (mmol/L) 39 1.7 (1.4, 1.9) 1.6 (1.4, 1.8) 314 0.25
Fasting BG (mmol/L) 40 5.2 (4.8, 5.3) 4.8 (4.5, 5.1) 173 <0.001
HbA1c (%) 32 5.2 (5.0, 5.4) 5.2 (4.9, 5.3) 205 0.90
Smoking (yes) 48 8 (16.7%) 56 (14.0%) 399 0.84
Anovulation (yes) 56 42 (75.0%) 388 (86.2%) 450 0.04
PCO (yes) 51 36 (70.5%) 370 (86.9%) 426 0.005
HA (yes) 47 30 (63.8%) 239 (55.8%) 428 0.29
HA + anovulation (yes) 40 21 (52.5%) 198 (51.3%) 386 0.89
Data presented as median (interquartile range) or n (%). P-values between women with elevated BP and normal BP.
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In the present study, BP was significantly higher in young, 
normal weight women with PCOS compared to controls. 
In women with PCOS, higher BP was associated with 
greater waist circumference and unfavorable cholesterol, 
which supported the importance of metabolic screening. 
Testosterone levels were not associated with BP in women 
with PCOS.
Our finding of higher BP in normal weight 
Scandinavian women with PCOS is supported by recent 
studies. Ollila et al. (6) studied PCOS as an independent risk 
factor for HT in normal weight women with self-reported 
PCOS (n = 100) in a population based cross-sectional study 
from the Northern Finland Birth Cohort. Ollila found 
that women with self-reported PCOS displayed higher BP 
by the age of 31 compared to controls (mean (s.d.) SBP 
120 (13) vs 117 (11) mmHg, P = 0.017 and DBP 76 (10) 
vs 72 (10) mmHg, P = 0.003) (6). Moreover, PCOS was 
associated with HT and increased cardiovascular morbidity 
independent of BMI (6). Pinola et al. found that overweight 
and obese Scandinavian women with PCOS (mean BMI 
29 kg/m2) had 5 mmHg higher SBP and 4 mmHg higher 
DBP compared to controls, which was present already 
from <30 years of age (17). Higher BP in women with 
PCOS remained significant after adjustment for BMI and 
age (17). Recently, we performed a national register based 
study in a Danish cohort of 18,112 women with PCOS 
and 52,769 controls where the main study outcome was 
CVD events including HT and dyslipidemia (5). Included 
women had average age of 29 years and median follow 
up of 11.1 years (5). The odds ratio for development of 
CVD including HT and dyslipidemia was 1.7 in PCOS and 
the risk of HT was dependent on baseline metabolic risk 
profile (SBP and DBP, BMI, waist, and triglycerides) (5). 
A total of 24% of women with PCOS and CVD were normal 
weight at the time of PCOS diagnosis (5). Holte et  al. 
applied 24 h BP measurements and found significantly 
Table 4 Bivariate associations with BP in women with PCOS and controls. 
n
PCOS Control
nSBP DBP SBP DBP 
Age (years) 512 0.07 (0.13) 0.10 (0.02) 0.19 (0.001) 0.28 (<0.001) 281
BMI (kg/m2) 512 0.15 (0.001) 0.13 (0.003) 0.19 (0.002) 0.11 (0.06) 281
Waist (cm) 472 0.15 (0.001) 0.15 (0.001) 0.36 (<0.001) 0.27 (<0.007) 123
WHR 466 0.19 (<0.001) 0.20 (<0.001) 0.39 (<0.001) 0.31 (<0.001) 123
T-testosterone (nmol/L) 360 0.14 (0.009) 0.11 (0.03) −0.03 (0.67) −0.02 (0.75) 248
Androgen Index 339 0.10 (0.07) 0.13 (0.02) 0.04 (0.58) 0.07 (0.28) 246
Cholesterol (mmol/L) 326 0.23 (<0.001) 0.20 (<0.001) 0.06 (0.52) 0.17 (0.08) 111
TG (mmol/L) 323 0.10 (0.06) 0.07 (0.19) 0.21 (0.03) 0.08 (0.39) 111
LDL (mmol/L) 298 0.22 (<0.001) 0.19 (<0.001) 0.11 (0.24) 0.06 (0.51) 111
HDL (mmol/L) 306 0.04 (0.49) 0.05 (0.40) 0.09 (0.32) 0.22 (0.02) 111
Fasting BG (mmol/L) 395 0.28 (<0.001) 0.19 (<0.001) 0.05 (0.65) −0.08 (0.43) 93
HbA1c (%) 205 0.03 (0.69) 0.06 (0.44) 0.31 (0.15) 0.21 (0.33) 43
Non-parametric associations between DBP, SBP, clinical, and biochemical characteristics in women with PCOS. Data presented as R-value (P).
Table 5 Predictors of SBP, multiple regression analyses in women with PCOS (n = 512). 
Model 1 (n = 472) Model 2 (n = 374) Model 3 (n = 299) Model 4 (n = 343) Model 5 (n = 130)




















Fasting BG X 2.1 (−0.7; 4.9)
P = 0.14
X X −0.89 (−5.3; 3.5)
P = 0.69
Cholesterol X X 3.9 (1.9; 6.0)
(P < 0.001)
X 4.2 (0.2; 8.1)
P = 0.04




R2 0.15 (P < 0.001) 0.16 (P < 0.001) 0.23 (P < 0.001) 0.24 (P < 0.001) 0.39 (P < 0.001)
Data represent β-coefficients (95% CI) and adjusted R2 values. All models were adjusted for country of origin (1: Denmark, 2: Finland, 3: Norway, 4: 
Sweden), age, and waist circumference. In model 3, 4, 5, additional independent variables included fasting blood glucose (BG), cholesterol, and total 
testosterone (T-testosterone), as shown in the respective models above. Bold indicates statistical significance.
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higher day-time systolic BP in Swedish women with PCOS 
(mean BMI 26 kg/m2), which persisted after adjusting for 
BMI, body fat distribution, and insulin resistance (23). 
In populations of other ethnic background than Nordic, 
Zachurzok-Buczynska et al. reported higher 24-h BP and 
higher day and night mean arterial BP in normal weight 
Polish women with PCOS compared to controls (24) and 
Bahri Khomami et al. found higher SBP in Iranian women 
with PCOS (mean BMI 26 kg/m2) compared to controls 
(25). Joham et  al. conducted a cross sectional study in 
8612 Australian women (500 women with PCOS, average 
BMI 28 kg/m2) and found higher risk of HT in normal 
weight women with PCOS vs controls (26). In regression 
analyses, there was a trend toward an association between 
PCOS and HT (odds ratio: 1.6, 95% CI: 0.9–2.6, P = 0.09), 
yet this did not reach significance (26). In contrast, other 
studies reported comparable BP in normal weight women 
with PCOS (originating from China (27) and Spain (28)) 
compared to controls. A recent meta-analysis found no 
difference in HT in non-obese women with and without 
PCOS (13). The number of participants included in the 
meta-analysis was limited, which resulted in a very wide 
CI for the odds ratio of HT in normal weight women with 
PCOS compared to controls 2.44 (0.80, 7.43), P = 0.11 
(13). Among BMI-matched studies, Lim et al. performed 
subgroup analyses according to geographic region and 
found a significantly increased risk of metabolic syndrome 
in normal weight women with PCOS from Europe, but 
not from other regions (7). Furthermore, the greatest 
increase in prevalence of metabolic syndrome in women 
with PCOS compared to controls was in American study 
populations, which the authors suggested was likely to be 
related to obesity (7). Whether the metabolic risk profile 
in European women with PCOS differs from women with 
PCOS originating from other continents remains to be 
determined.
BP increased with age in the present study. 
Interestingly, the prevalence of BP > 140/90 mmHg 
was different between women with PCOS and controls. 
No control women with BMI < 25 kg/m2 and age < 35 
years had BP ≥ 140/90 mmHg, while the corresponding 
prevalence in women with PCOS was 10.9%. This finding 
supported that young normal-weight women with 
PCOS need attention regarding BP measurement. The 
absolute level of SBP and DBP was not remarkably high. 
In European guidelines, BP lowering drug treatment is 
recommended with office BP ≥ 140/90 mmHg and >5% 
fatal CVD risk (22). However, previous studies reported 
that the risk for CVD increases in a log-linear fashion 
already from SBP levels < 115 mmHg to > 180 mmHg, 
and from DBP levels < 75 mmHg to > 105 mmHg (29, 30). 
These risk gradients were homogenous across subgroups 
of sex and ethnicity (29).
Waist circumference and lipid status were the most 
important determinants of BP in our normal weight 
study cohort of women with PCOS. These findings were 
in accordance with studies in populations without PCOS 
that showed a close relation between BMI and BP with 
no evidence of a threshold for BMI (31). Furthermore, 
for cholesterol levels in the range 5.2–11.6 mmol/L, 
each 1 mmol/L increase was associated with 7% higher 
mortality (32). Recent findings suggested that young 
individuals are more affected by higher lipid levels than 
older individuals. In the age groups of 18–34, 35–44, 
45–54, 55–64, 65–74, and 75–99 years, each 1 mmol/L 
higher level for total cholesterol ≥ 5.2 mmol/L, increased 
mortality by 14, 13, 8, 7, 6, and 3%, respectively (32). 
HbA1c and blood glucose is associated with all-cause 
Table 6 Predictors of DBP, multiple regression analyses in women with PCOS (n = 512). 
Model 1 (n = 472) Model 2 (n = 374) Model 3 (n = 299) Model 4 (n = 343) Model 5 (n = 130)




















F-Glucose X −0.23 (−2.2; 1.8)
P = 0.82
X X 0.11 (−3.0; 3.3)
P = 0.94
Cholesterol X X 1.9 (0.47; 3.3)
(P < 0.001)
X 2.4 (−0.40; 5.2)
P = 0.09




R2 0.15 (P < 0.001) 0.16 (P < 0.001) 0.21 (P < 0.001) 0.23 (P < 0.001) 0.39 (P < 0.001)
Data represent β-coefficients (95% CI) and adjusted R2 values. All models were adjusted for country of origin (1: Denmark, 2: Finland, 3: Norway, 4: 
Sweden), age and, waist circumference. In model 3, 4, 5, additional independent variables included fasting blood glucose (BG), cholesterol, and total 
testosterone (T-testosterone), as shown in the respective models above. Bold indicates statistical significance.
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mortality also in individuals without T2D (33, 34), and 
the association between glucose and mortality is closer 
at younger ages (35). Our findings suggest that the same 
metabolic risk markers are relevant in women with PCOS 
as in other study populations. Our results demonstrate 
that waist circumference and lipid status have the highest 
impact on SBP, supporting the hypothesis that lifestyle 
intervention is important also in young and normal 
weight women with PCOS. Furthermore, intervention 
against metabolic risk could be of special relevance in 
young study cohorts, especially if BP is increased (16). 
We did not standardize insulin measurement across 
counties, and therefore, these data were not included 
in the present manuscript. Insulin resistance could be 
a mediator of metabolic risk in women with PCOS (36) 
and this hypothesis should be further evaluated in future 
studies. Obstructive sleep apnea is associated with higher 
risk of metabolic disease including HT (37). The risk of 
obstructive sleep apnea in normal weight women with 
PCOS and HT should be further investigated in future 
studies.
Testosterone showed a positive association with BP 
in bivariate analyses. In regression analyses, however, the 
impact of testosterone on BP was not significant. These 
results could be explained by an interaction between 
higher testosterone, central obesity, and metabolic risk, 
which is also observed in obese women with PCOS (4). 
In accordance, Pinola et al. (17) found that higher BP in 
women with PCOS was not related to whether the women 
were normo- or hyperandrogenic. Androgen levels decline 
in ageing women with PCOS (38, 39) and the impact of 
testosterone on BP in ageing women with PCOS could 
decline compared to metabolic risk factors such as central 
obesity, lipid status, and blood glucose levels.
Strengths and limitations apply to the present 
study. We included a large and well-characterized study 
population of homogenous ethnicity, which was a major 
strength of the study. However, the study cohort included 
women referred to outpatient clinics, which could imply 
a more severe PCOS phenotype. The women participating 
in the present study were included in other publications 
from the author group (11, 16, 17), which could infer 
study bias. We only allowed gold standard steroid 
measurements in the present study (mass spectrometry 
or ether extraction followed by RIA), but differences in 
applied steroid analyses between study centers could 
have affected study results. In regression analyses, we 
corrected for country of diagnosis, but we have been 
cautious regarding conclusions including results from 
these measurements.
A major limitation of this study was that seven 
different study centers were involved, which implied 
different methods of BP measurement and in most cases 
only one office BP measurement was performed. The 
applied methods in all centers resembled methods for 
measuring BP in a daily clinic, which may represent a 
study strength. However, it is important to recognize that 
diagnosis and classification of elevated BP should be based 
on ≥2 readings obtained on ≥2 occasions in order not to 
overestimate the prevalence of HT (20). BP measurements 
were obtained in a similar way in women with PCOS and 
controls and the limitation of only one BP measurement 
did not affect the observed differences between the study 
cohorts. However, the current study design does not allow 
us to draw conclusions on the prevalence of diagnosis of 
HT and indication for medical treatment for HT in the 
study cohort. Furthermore, the study should be repeated 
in populations of other ethnic background.
Taken together, we found that young and normal 
weight women with PCOS had higher BP compared to age 
and BMI matched controls. In women with PCOS, BP was 
positively associated with waist and lipid status, which 
underlined the importance of metabolic screening also in 
young and normal weight women with PCOS.
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